[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100485010":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":54,"centralContacts":59,"locations":68,"responsibleParty":162,"collaborators":164,"id":170,"slug":171,"hasResults":172,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":44,"eligibilityCriteria":176,"healthyVolunteers":172,"sex":177,"minAge":44,"maxAge":44,"enrollmentInfo":178,"targetDuration":44,"studyType":181,"phases":182,"briefSummary":184,"conditions":185,"keywords":44,"overallStatus":71,"whyStopped":44,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":198},{"fullName":5,"class":6},"Jonsson Comprehensive Cancer Center","OTHER",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A (fisetin)","EXPERIMENTAL","Patients receive fisetin PO on days 1, 2, and 3. Treatment repeats every 2 weeks for up to 8 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples throughout the trial.",[13,14,15,16],"Procedure: Biospecimen Collection","Drug: Fisetin","Other: Quality-of-Life Assessment","Other: Questionnaire Administration",{"label":18,"type":19,"description":20,"interventionNames":21},"Arm B (placebo)","PLACEBO_COMPARATOR","Patients receive placebo PO on the trial. on days 1, 2, and 3. Treatment repeats every 2 weeks for up to 8 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples throughout the trial.",[13,22,15,16],"Drug: Placebo Administration",[24,33,41,45,51],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"PROCEDURE","Biospecimen Collection","Undergo collection of blood samples",[9,18],[30,31,32],"Biological Sample Collection","Biospecimen Collected","Specimen Collection",{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"DRUG","Fisetin","Given PO",[9],[39,40],"3,3',4',7-Tetrahydroxyflavone","7,3',4'-Flavon-3-ol",{"type":34,"name":42,"description":36,"armGroupLabels":43,"otherNames":44},"Placebo Administration",[18],null,{"type":6,"name":46,"description":47,"armGroupLabels":48,"otherNames":49},"Quality-of-Life Assessment","Ancillary studies",[9,18],[50],"Quality of Life Assessment",{"type":6,"name":52,"description":47,"armGroupLabels":53,"otherNames":44},"Questionnaire Administration",[9,18],[55],{"name":56,"affiliation":57,"role":58},"Mina S. Sedrak, MD","UCLA \u002F Jonsson Comprehensive Cancer Center","PRINCIPAL_INVESTIGATOR",[60,64],{"name":56,"role":61,"phone":62,"phoneExt":44,"email":63},"CONTACT","310-825-3181","msedrak@mednet.ucla.edu",{"name":65,"role":61,"phone":66,"phoneExt":44,"email":67},"Kelly Synold","424-440-3877","ksynold@mednet.ucla.edu",[69,85,96,107,128,140,151],{"facility":70,"status":71,"city":72,"state":73,"zip":74,"country":75,"countryCode":76,"cosmosGeoPoint":77,"geoPoint":82,"contacts":83},"UCLA Health Cancer Care in Alhambra","RECRUITING","Alhambra","California","91801","United States","US",{"type":78,"coordinates":79},"Point",[80,81],-118.12701,34.09529,{"lat":81,"lon":80},[84],{"name":56,"role":61,"phone":62,"phoneExt":44,"email":63},{"facility":86,"status":71,"city":87,"state":73,"zip":88,"country":75,"countryCode":76,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"UCLA Health Beverly Hills Primary & Specialty Care","Beverly Hills","90210",{"type":78,"coordinates":90},[91,92],-118.40036,34.07362,{"lat":92,"lon":91},[95],{"name":56,"role":61,"phone":62,"phoneExt":44,"email":63},{"facility":97,"status":71,"city":98,"state":73,"zip":99,"country":75,"countryCode":76,"cosmosGeoPoint":100,"geoPoint":104,"contacts":105},"UCLA Health Burbank Primary & Specialty Care","Burbank","91505",{"type":78,"coordinates":101},[102,103],-118.30897,34.18084,{"lat":103,"lon":102},[106],{"name":56,"role":61,"phone":62,"phoneExt":44,"email":63},{"facility":108,"status":71,"city":109,"state":73,"zip":110,"country":75,"countryCode":76,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"City of Hope Comprehensive Cancer Center","Duarte","91010",{"type":78,"coordinates":112},[113,114],-117.97729,34.13945,{"lat":114,"lon":113},[117,121,126],{"name":118,"role":61,"phone":119,"phoneExt":44,"email":120},"Keilani Luna","909-809-9338","kluna@coh.org",{"name":122,"role":61,"phone":123,"phoneExt":124,"email":125},"Marie D. Yee, MD","626-256-4673","85200","lyee@coh.org",{"name":127,"role":58,"phone":44,"phoneExt":44,"email":44},"Lisa D. Yee, MD",{"facility":57,"status":71,"city":129,"state":73,"zip":130,"country":75,"countryCode":76,"cosmosGeoPoint":131,"geoPoint":135,"contacts":136},"Los Angeles","90095",{"type":78,"coordinates":132},[133,134],-118.24368,34.05223,{"lat":134,"lon":133},[137,139],{"name":138,"role":61,"phone":62,"phoneExt":44,"email":63},"Mina S. Sedrak",{"name":138,"role":58,"phone":44,"phoneExt":44,"email":44},{"facility":141,"status":71,"city":142,"state":73,"zip":143,"country":75,"countryCode":76,"cosmosGeoPoint":144,"geoPoint":148,"contacts":149},"UCLA Health Primary Care in Marina del Rey","Marina del Rey","90292",{"type":78,"coordinates":145},[146,147],-118.45371,33.98162,{"lat":147,"lon":146},[150],{"name":56,"role":61,"phone":62,"phoneExt":44,"email":63},{"facility":152,"status":71,"city":153,"state":73,"zip":154,"country":75,"countryCode":76,"cosmosGeoPoint":155,"geoPoint":159,"contacts":160},"UCLA Health Primary Care in Pasadena","Pasadena","91105",{"type":78,"coordinates":156},[157,158],-118.14452,34.14778,{"lat":158,"lon":157},[161],{"name":56,"role":61,"phone":62,"phoneExt":44,"email":63},{"type":163,"investigatorFullName":44,"investigatorTitle":44,"investigatorAffiliation":44,"oldNameTitle":44,"oldOrganization":44},"SPONSOR",[165,168],{"name":166,"class":167},"National Cancer Institute (NCI)","NIH",{"name":169,"class":167},"National Institute on Aging (NIA)","100485010","phase-2-fisetin-to-improve-physical-function-in-stage-i-iii-breast-cancer-survivors-100485010",false,"NCT05595499","Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors","A Phase II Randomized Double-Blind Placebo-Controlled Study of Fisetin to Improve Physical Function in Breast Cancer Survivors","Inclusion Criteria:\n\n* Women who are postmenopausal at the start of study treatment.\n\nPostmenopausal status will be established as follows:\n\n* Women aged: \\>= 60 years OR\n* Women aged \\\u003C 60 years AND one of the following conditions is met:\n\n  * They have not had any menstrual periods for at least 12 months in the absence of exogenous hormonal treatments, chemotherapy, and\u002For tamoxifen AND have serum estradiol and follicle-stimulating hormone (FSH) levels confirmed as being within the standard laboratory reference range for postmenopausal females.\n  * They have documented irreversible bilateral oophorectomy.\n  * They are receiving ovarian suppression with their breast cancer endocrine therapy\n\n    * Women with a diagnosis of early-stage breast cancer (Stage I-III) treated with neo\u002Fadjuvant chemotherapy within 12 months of starting study treatment\n    * No evidence of active\u002Frecurrent breast cancer or other serious chronic illnesses\n    * Have evidence of frail health, defined as a diminished 6-minute walk distance (\\\u003C 400m) at baseline\n    * Platelets \\> 60,000\u002Fmm\\^3\n    * White blood cell count \\> 2,000\u002Fmm\\^3\n    * Absolute neutrophil count \\> 500\u002Fmm\\^3\n    * Hemoglobin \\>= 8.0 g\u002FdL\n    * Total bilirubin =\\\u003C 3.0 X upper limit of normal (ULN)\n    * Aspartate aminotransferase (AST) =\\\u003C 4.0 x ULN\n    * Alanine aminotransferase (ALT) =\\\u003C 4.0 x ULN\n    * Estimated glomerular filtration rate (eGFR) of \\>= 30mL\u002Fmin\u002F1.73m\\^2 per the Modification of Diet in Renal Disease (MDRD) calculation\n    * Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Cancer-directed chemotherapy, biological therapy, or immunotherapy within 30 days prior to the start of study treatment. Exceptions include: trastuzumab, pertuzumab, pembrolizumab, tamoxifen, ribociclib, abemaciclib, aromatase inhibitors and\u002For ovarian suppression.\n* Surgery and\u002For radiation within the last 30 days of starting study treatment (Exception: invasive non- major procedures such as an outpatient biopsy)\n* Subjects taking medications that are considered prohibited.\n\n  * Exception: Subjects taking any of the medications listed in under \"Temporary medication adjustment required\" may participate if they are otherwise eligible AND the medication can be safely withheld (from immediately before the 1st study agent administration until at least 10 hours after the last study agent administration, for each dosing interval)\n* On herbal and natural medications with possible senolytic properties (i.e., curcumin, kava kava, St. John's wort) and are unable or unwilling to hold its administration 2 days prior to and during study treatment dosing. Exceptions include cannabidiol (CBD), vitamins, probiotics, and fish oil. Other herbal and natural medications may be permitted or prohibited per clinician discretion\n* Subjects taking potentially senolytic agents within the last year: fisetin, quercetin, luteolin, dasatinib or imatinib (or other tyrosine kinase inhibitors), piperlongumine, or navitoclax\n* Subjects on therapeutic doses of anticoagulants (e.g., warfarin, heparin, low molecular weight heparin, factor Xa inhibitors, etc.)\n* Issues with tolerating oral medication (such as but not limited to, inability to swallow pills (g-tubes not allowed), malabsorption issues, ongoing nausea or vomiting during screening, history of Crohn's, gastric bypass\u002Freduction, or celiac disease)\n* Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures\n* Currently participating in another intervention research study seeking to improve functional status, alleviate frailty, muscle strength, exhaustion\u002Ffatigue, or cognitive function","FEMALE",{"count":179,"type":180},88,"ESTIMATED","INTERVENTIONAL",[183],"PHASE2","This phase II trial tests whether fisetin works to improve physical function in women who have received chemotherapy for stage I-III breast cancer treatment. Fisetin is a naturally occurring substance that is found in strawberries and other foods. Fisetin eliminates cells that have undergone a process called senescence. Senescence is when a cell ages and permanently stops dividing but does not die. Over time, large numbers of these cells build up in tissues throughout the body and can release harmful substances that causes inflammation and damages nearby healthy cells. Studies have shown that chemotherapy causes a build-up of these senescent cells. Giving fisetin may eliminate senescent cells and improve physical function in postmenopausal women who have received chemotherapy for breast cancer.",[186,187,188],"Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","2026-07-16",{"date":191,"type":192},"2026-07-17","ACTUAL",{"date":194,"type":192},"2023-03-27",{"date":196,"type":180},"2028-08-14",{"name":5,"class":6},7]